MARKET

UPB

UPB

UpStream Bio Inc.
NASDAQ
30.27
+1.06
+3.63%
Closed 16:56 12/24 EST
OPEN
29.65
PREV CLOSE
29.21
HIGH
30.76
LOW
29.60
VOLUME
266.48K
TURNOVER
--
52 WEEK HIGH
33.00
52 WEEK LOW
5.14
MARKET CAP
1.64B
P/E (TTM)
-13.1489
1D
5D
1M
3M
1Y
5Y
1D
Upstream Bio (UPB): Reassessing Valuation After NASDAQ Biotechnology Index Inclusion and Sharp 3‑Month Rally
Simply Wall St · 3d ago
Weekly Report: what happened at UPB last week (1215-1219)?
Weekly Report · 4d ago
Does Mizuho’s New Coverage of Upstream Bio (UPB) Reframe the Stock’s Risk‑Reward Narrative?
Simply Wall St · 6d ago
Evercore ISI Keeps Their Buy Rating on Upstream Bio, Inc. (UPB)
TipRanks · 12/19 09:26
Upstream Bio Initiated at Outperform by Mizuho
Dow Jones · 12/18 09:47
Upstream Bio Price Target Announced at $51.00/Share by Mizuho
Dow Jones · 12/18 09:47
Mizuho Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $51
Benzinga · 12/18 09:36
U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar
Reuters · 12/18 06:42
More
About UPB
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.

Webull offers UpStream Bio Inc. stock information, including NASDAQ: UPB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UPB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UPB stock methods without spending real money on the virtual paper trading platform.